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B R I E F  R E P O R T
Disseminated Cryptococcosis With 
Brain Involvement in Patients With 
Chronic Lymphoid Malignancies on 
Ibrutinib
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Dimitrios P. Kontoyiannis,3 and John R. Perfect1
1Department of Medicine, Duke University, Durham, North Carolina; 2Division of Infectious 
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We report 2 cases of disseminated cryptococcosis with central 
nervous system involvement in patients with chronic lymphoid 
malignancies occurring within 1 month of starting on ibrutinib. 
Characteristically, in both cases, no inflammation was seen in 
the cerebrospinal fluid. Central nervous system mycoses should 
be considered as a potential complication of ibrutinib.
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Patients with hematologic malignancies including indolent 
lymphoproliferative disorders have pleiotropic immune deficits 
due to their underlying disease, placing them at risk for oppor-
tunistic infections, such as invasive fungal infections (IFIs) [1]. 
Cryptococcosis is an IFI that has previously been described 
in this patient population, particularly associated with receipt 
of fludarabine or corticosteroids [2, 3]. Ibrutinib is a Bruton’s 
tyrosine kinase (BTK) inhibitor used to treat lymphoprolifer-
ative disorders that has demonstrated significant improvement 
in progression-free survival in clinical trials [4, 5]. Two cases of 
cryptococcal infections were reported in the clinical trials for 
ibrutinib including one death from cryptococcal pneumonia 
[6, 7]. In this study, we report 2 cases of disseminated crypto-
coccosis due to Cryptococcus neoformans with central nervous 
system (CNS) involvement but no inflammation in patients 
with chronic lymphoid malignancies at our center, both occur-
ring within 1 month of starting ibrutinib therapy.
CASE 1
An 88-year-old white man with indolent lymphoma started 
therapy with ibrutinib 420 mg daily in 2015 due to progressive 
disease. Initial diagnosis of lymphoplasmacytic lymphoma 
was made in 1998, and previous therapies included rituximab 
in 2008 and R-Bendamustine in 2012. Approximately 3 weeks 
into starting ibrutinib therapy, the patient developed shortness 
of breath and pleuritic chest pain. He was lymphopenic (total 
T cells 400/liter) but not neutropenic at that time. A comput-
erized tomography (CT) scan revealed a 1.3-cm, right para-
mediastinal spiculated lung lesion suspicious for primary lung 
cancer. The patient did not have any fevers or weight loss at 
this time, but ibrutinib therapy was withheld in the midst of 
further evaluation. One week later, he developed fevers up 
to 39°C and was treated with levofloxacin [8]. However, he 
then developed worsening fatigue, new nonproductive cough, 
and headache, which prompted hospital admission. Positron 
emission tomography-CT scan showed an 8-cm, right para-
mediastinal mass with increased fluorodeoxyglucose (FDG) 
activity, multiple enlarged, FDG-avid mediastinal lymph 
nodes thought to be consistent with progression of his under-
lying disease. Computerized tomography scan of the brain 
without contrast did not show an acute intracranial process. 
For further diagnostic work-up, the patient underwent medi-
astinoscopy with lymph node biopsy, and pathology showed 
necrotizing granulomatous lymphadenitis of level 3 and 4R 
lymph nodes with yeasts morphologically consistent with 
Cryptococcus. Fungal culture from one of the lymph nodes had 
no growth of organism. Serum cryptococcal antigen titer was 
positive at 1:40. The patient was started on liposomal ampho-
tericin B (L-AMB) 3  mg/kg daily and flucytosine (5-FC) 
25 mg/kg every 6 hours [9, 10]. With an ongoing headache, 
he underwent lumbar puncture (LP) that showed an opening 
pressure of 7 cm of cerebrospinal fluid (CSF). Cerebrospinal 
fluid analysis revealed 3 nucleated cells/mm3 (normal cell 
count 0–5/mm3), 29 red blood cells (RBCs)/mm3 (normal ≤0 
cells/mm3), glucose 57 mg/dL, and protein 43 mg/dL (normal 
range 15–50 mg/dL). The patient’s serum glucose on this day 
was 158 mg/dL (normal range 70–140 mg/dL) with a resultant 
CSF to serum glucose ratio of 0.36. Cerebrospinal fluid cryp-
tococcal antigen was negative, but CSF fungal culture grew 
Cryptococcus, and the species, C neoformas, was identified 
by matrix-assisted laser desorption/ionization time of flight. 
From follow-up LP results 2 weeks after starting L-AMB/5-FC 
induction therapy, CSF cryptococcal antigen remained nega-
tive, and fungal culture was negative for Cryptococcus, so the 
patient was transitioned to oral fluconazole 400 mg daily [11]. 
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Follow-up CT chest imaging revealed a decrease in right par-
amediastinal mass size. The patient ultimately recovered from 
disseminated cryptococcosis and remains on lifelong flucona-
zole suppressive therapy (200  mg daily) as he has restarted 
chemotherapy.
CASE 2
A 54-year-old African American man with a history of chronic 
lymphocytic leukemia (CLL), bronchiolitis obliterans organizing 
pneumonia (BOOP), morbid obesity, diabetes mellitus, hyperten-
sion, and chronic kidney disease presented with nonproductive 
cough and fever approximately 1  month after starting ibrutinib 
therapy (dosed 420 mg daily) in 2016. He was not neutropenic or 
lymphopenic at this time. The patient was diagnosed with CLL in 
2012 and had previously been treated with fludarabine, cyclophos-
phamide, and rituximab from 2014 to 2015. Upon hospital admis-
sion, he denied headache, nausea, vomiting, or visual changes 
but was febrile to 39.1°C and hypoxic requiring supplemental 
oxygen. Chest imaging revealed bilateral lower lobe ground-glass 
opacities consistent with either atypical infection or drug toxic-
ity as well as bulky mediastinal and axillary lymphadenopathy 
consistent with his underlying CLL. The patient was started on 
broad-spectrum antibiotics, corticosteroids in view of his history 
of BOOP, and ibrutinib was withheld pending further work-up of 
possible drug-induced pneumonitis. He underwent bronchoscopy 
with transbronchial biopsy and bronchoalveolar lavage (BAL). 
Pathology from the biopsy demonstrated yeasts on Gomori meth-
enamine silver stain, most consistent with Cryptococcus. Blood 
and BAL cultures grew C neoformans. The patient was started 
on L-AMB 5 mg/kg daily and 5-FC 25 mg/kg every 6 hours for 
disseminated cryptococcosis. However, he developed acute res-
piratory failure and septic shock and was transferred to the inten-
sive care unit (ICU) necessitating mechanical ventilation and 
continuous veno-venous hemofiltration (CVVH). Computerized 
tomography scan of the brain without contrast performed before 
LP did not show an acute intracranial process. Lumbar puncture 
was performed without a report of an opening pressure, and CSF 
analysis revealed 4 nucleated cells, 6 RBCs, glucose 157  mg/dL, 
protein 30 mg/dL, negative CSF cryptococcal antigen, and a fungal 
culture grew C neoformans [12]. In total, the patient was treated 
with L-AMB for approximately 28 days, 5-FC for 14 days, and flu-
conazole (dosed 800 mg intravenous daily for CVVH) for approxi-
mately 14 days after discontinuation of 5-FC. The L-AMB duration 
of therapy was extended to 28 days because repeat LP attempts at 
bedside were unsuccessful, and the ICU team assessed the patient’s 
clinical status to be too tenuous to transport to interventional radi-
ology for an image-guided attempt. Three weeks into his ICU stay, 
the patient once again developed profound systemic shock, pro-
gressive respiratory failure, and lactic acidosis of unclear etiology 
as blood cultures were negative at this time. His status declined fur-
ther despite full support, the decision was made to withdraw care, 
and the patient died Characteristics from both cases are depicted 
in Table 1.
DISCUSSION
The association between ibrutinib and risk for IFI with a pro-
pensity for CNS invasion has previously been reported, and it 
is not limited to Cryptococcus. Specifically, Ruchlemer et al [13] 
reported 3 cases of invasive aspergillosis with CNS predilection 
Table 1. Demographics of the Invasive Fungal Infections
Clinical Feature Case 1 Case 2
Underlying disease Indolent lymphoplasmacytic lymphoma Chronic lymphocytic leukemia
HIV-1/2 antibody testing Negative Negative
Age (years) 88 54
Time from starting ibrutinib to infection presentation 3 weeks 4 weeks
WBC counta (×109/liter)b
Absolute neutrophil count (×109/liter)c







Serum cryptococcal antigen titer 1:40 Not obtained
Sites of documented cryptococcal involvement Lung, CSF Blood, lung, CSF
CSF opening pressure (cm CSF) 7 Not recorded
CSF nucleated cells 1 4
CSF protein (mg/dL) 43 30
CSF glucose (mg/dL) 57 157
CSF India ink stain Negative Negative
CSF fungal culture Cryptococcus neoformans C neoformans
Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; WBC, white blood cell.
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in patients on ibrutinib within 2 months of drug initiation and 
concurrent glucocorticoids. The authors noted that 2 patients 
had documented Aspergillus brain abscesses, and 1 patient had 
documented sinusitis with suspected CNS involvement. Here, 
we described for the first time 2 cases of disseminated cryp-
tococcosis with CNS involvement but a noninflammatory CSF 
analysis and negative CSF cryptococcal antigen titers, both 
presenting approximately 1 month after starting ibrutinib. The 
poor outcome of the second case reflects an overwhelming 
infection and cryptococcemia. Cryptococcemia has been long 
described as a marker of high fungal burden and a poor prog-
nostic factor in cryptococcosis [14].
Okamoto et  al [15] have reported a case of disseminated 
cryptococcosis due to C neoformans in a patient with CLL 
approximately 1  month after starting ibrutinib with docu-
mented blood and suspected lung involvement. The early onset 
of disseminated cryptococcosis after the initiation of ibrutinib 
is similar to what occurred in our 2 cases and suggests that these 
patients had preceding pulmonary colonization with C neofor-
mans. Of note, patients with chronic lymphoid malignancies 
are already at risk for disseminated infection due to immuno-
suppression from their underlying diseases and chemotherapy, 
but we propose that this risk may have been exacerbated by the 
initiation of ibrutinib. Whether the amplification of the risk is 
directly due to BTK inhibition or an off-target effect of ibrutinib 
requires further evaluation.
One potential mechanism is the role of caspase recruitment 
domain (CARD) homologs in facilitating entry and propaga-
tion of infection by fungal organisms in the CNS. The CARD 
homologs (CARD9, 10, and 11) form heterotrimers with B-cell 
lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue 
lymphoma-translocation gene 1 (MALT1) to produce CARD-
BCL10-MALT1 (CBM) complexes [16]. The CBM complexes 
activate nuclear factor κβ, which plays a critical role in regu-
lation of the innate and adaptive immune systems and apop-
tosis [17]. CARD11, found in lymphocytes, is a key player in 
the CBM complex downstream of the B-cell receptor and BTK, 
the target for ibrutinib [18]. CARD9, found in myeloid cells, is 
a signaling adaptor used by C-lectin receptors, which are types 
of pattern recognition receptors and are involved in neutro-
phil recruitment and proinflammatory cytokine production in 
antifungal immunity [19]. Patients with CARD9 deficiency are 
uniquely susceptible to invasive fungal infections of the CNS 
due to diminished neutrophil accumulation in the brain [20]. 
Therefore, CARD9 could be essential for a complex similar to 
CBM in CNS macrophages and microglial cells, which is poten-
tially affected by ibrutinib.
An unusual feature of the present cases is the noninflamma-
tory CSF profile. In fact, the yeasts may have arrived quickly in 
the CNS after the start of ibrutinib because there was a negative 
CSF cryptococcal antigen despite positive CSF cultures for C 
neoformans. A  similar finding of noninflammatory CSF with 
negative India ink stain and negative CSF cryptococcal anti-
gen has been reported in a case of cryptococcal meningitis in a 
patient with Hodgkin’s lymphoma [21]. One possible explana-
tion of the noninflammatory CSF profile was that the dissemi-
nated infection was detected relatively early in the course before 
a detectable level of antigen could be achieved in the CSF. In 
contrast, the noninflammatory CSF analysis may be due to an 
immune defect similar to that seen in acquired immunodefi-
ciency syndrome, where 25%–30% of patients will have normal 
CSF profiles despite CNS infection documented by positive 
fungal cultures [22, 23].
CONCLUSIONS
Ibrutinib shows promise for improving disease progres-
sion-free survival in otherwise difficult-to-treat chronic 
lymphoid malignancies, but cases of IFI with CNS involve-
ment, specifically aspergillosis and cryptococcosis, seen 
shortly after drug initiation should raise caution to use of 
ibrutinib. The extent of immunosuppression and immuno-
genetic risks for this complication of ibrutinib therapy are 
unknown. Clinicians should be vigilant, and IFIs should 
be included in the differential diagnosis in patients with 
suspected infectious complications on ibrutinib therapy. 
Further study of the potential association between ibrutinib 
and IFI could offer insight into the immune implications of 
ibrutinib as well as host-pathogen interactions of dissemi-
nated cryptococcosis.
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